Literature DB >> 6715608

Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine.

T Y Woo, J P Callen, J J Voorhees, D R Bickers, R Hanno, C Hawkins.   

Abstract

Dermatomyositis (DM) is a collagen vascular disease with prominent cutaneous findings. Although the myositis often responds to therapy with corticosteroids and/or immunosuppressives, the cutaneous disease may not respond. Seven patients with cutaneous lesions of DM that had not responded to therapy were treated with hydroxychloroquine in an open study. Three patients had idiopathic DM, one had DM without myositis, one had DM with malignancy, and one had adolescent DM. The response to the addition of hydroxychloroquine was good in all of the patients, and three had total resolution of their skin lesions. In two patients the corticosteroid dosage could be tapered. Therapy with hydroxychloroquine did not appear to have any beneficial effect on the myositis. We conclude that hydroxychloroquine may have a role as an adjuvant to the therapy of patients with cutaneous lesions of DM.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6715608     DOI: 10.1016/s0190-9622(84)80263-7

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  20 in total

Review 1.  Current management of polymyositis and dermatomyositis.

Authors:  C V Oddis; T A Medsger
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

Review 2.  [Current treatments of dermatomyositis and polymyositis].

Authors:  J Richter; C Iking-Konert
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

3.  Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids.

Authors:  Deborah M Levy; C April Bingham; Philip J Kahn; Andrew H Eichenfield; Lisa F Imundo
Journal:  J Pediatr       Date:  2009-10-28       Impact factor: 4.406

Review 4.  Recognition and management of myositis.

Authors:  P Cherin
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

5.  Cutaneous manifestations of dermatomyositis and their management.

Authors:  Jeffrey P Callen
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

Review 6.  Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review.

Authors:  Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

7.  Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.

Authors:  Paige W Wolstencroft; Livia Casciola-Rosen; David F Fiorentino
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

Review 8.  Inflammatory myopathy in a patient with cutaneous findings of pityriasis rubra pilaris: a case of Wong's dermatomyositis.

Authors:  Roberto Caporali; Lorenzo Cavagna; Mario Bellosta; Laura Bogliolo; Carlomaurizio Montecucco
Journal:  Clin Rheumatol       Date:  2003-11-12       Impact factor: 2.980

Review 9.  Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?

Authors:  Richard D Sontheimer
Journal:  Ann Transl Med       Date:  2018-04

Review 10.  Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.

Authors:  Hobart W Walling; Pedram Gerami; Richard D Sontheimer
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.